PTC Therapeutics, Inc. (PTC) is a leading, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients suffering from rare disorders. The company was founded in 1998 and is headquartered in South Plainfield, New Jersey, USA.
PTC’s approach to drug discovery is based on its proprietary RNA-based technologies, mainly targeting conditions where no effective treatments exist. This involves expediting the development of new treatments by identifying diseases caused by defects in protein production and restoring the production of functional proteins. Since its inception, PTC Therapeutics has revolutionized the treatment of rare diseases by developing innovative therapies that target the root causes of the conditions rather than just addressing the symptoms.
The company's pipeline includes treatments for Duchenne muscular dystrophy (DMD), cystic fibrosis, and other rare diseases. Its portfolio is led by Translarna™ (ataluren) and Emflaza® (deflazacort), both of which have been approved for treating Duchenne muscular dystrophy. Translarna is the first approved treatment that targets an underlying genetic cause of DMD, while Emflaza is a corticosteroid shown to delay the progression of the disease. In addition to these, PTC Therapeutics has various treatments in different stages of clinical trials for a range of other rare diseases.
PTC’s mission is driven by the passion to develop cutting-edge therapies that will make a significant difference in the lives of patients battling these serious conditions. The company dedicates considerable resources towards research and development to expand their understandings of rare genetic disorders and develop innovative therapies to treat them. This scientifically rigorous and patient-focused approach has helped the company establish a strong foothold in the biopharmaceutical industry.
PTC Therapeutics, Inc. is publicly traded on NASDAQ under the ticker symbol PTCT. The company has approximately 1,000 employees across its various multinational locations, including the United States, South America, and Europe.
It's worth mentioning that PTC is committed to the global community, providing patient assistance programs and pursuing collaborations with patient advocacy groups, as well as investing in physician education and scientific research initiatives to foster a comprehensive, well-informed approach to patient care.
In summary, PTC Therapeutics, Inc. is an innovative leader in the global biopharmaceutical industry, dedicated to improving the lives of patients with rare disorders through the development and commercialization of novel, patient-centric therapies.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
PTC Therapeutics (PTCT) has seen a 175% stock increase over the past three years, prompting questions about its current valuation relative to sales. Despite a P/S ratio of 5.2x, which is below the biotech industry average, Simply Wall St's Fair Ratio model suggests the stock is overvalued based on its fundamentals, including growth, margins, size, and risk. The company's acquisition of the ST-920 Fabry disease gene therapy program and future commercial delivery are key factors that could potentially justify a higher multiple.
Cantor Fitzgerald increased its price target for PTC Therapeutics (NASDAQ:PTCT) to $137.00 from $130.00, maintaining an "overweight" rating and suggesting a nearly 110% upside. The biopharmaceutical company has a "Moderate Buy" consensus rating among analysts, with an average price target of $99.08, despite its shares trading near their 52-week low. PTC Therapeutics recently surpassed quarterly expectations with $0.92 EPS and $360.52 million in revenue, a 101.5% year-over-year increase.
Bank of America Corp DE has acquired a new position of 1.45 million shares, valued at $118.46 million, in PTC Therapeutics during the second quarter, representing 1.74% of the company. This comes as several other institutional investors also initiated positions, while company insiders sold approximately $15.1 million of stock in the last 90 days. PTC Therapeutics reported strong quarterly results, beating EPS and revenue estimates, and analysts maintain a "Moderate Buy" consensus with an average price target of $98.50.
Wall Street Zen has upgraded PTC Therapeutics (NASDAQ:PTCT) to a "strong-buy" rating, despite a broader analyst consensus of "Moderate Buy" and a target price of $98.50. This upgrade follows stronger-than-expected quarterly results, with EPS of $0.92 against a $0.24 consensus and revenue up 101.5% year-over-year. However, the stock opened below its 50-day and 200-day moving averages, and insiders have sold approximately $15.1 million worth of stock in the last 90 days.
Michael Schmertzler, a director at PTC Therapeutics (NASDAQ:PTCT), sold 10,000 shares of the company's stock for $671,200. This sale was conducted under a pre-arranged Rule 10b5-1 trading plan, reducing his holdings to 1,306,594 shares. The transaction follows several other sales by Schmertzler in recent months, while the company's shares recently dropped 3.9% despite reporting stronger-than-expected earnings and revenue.
Michael Schmertzler, a director at PTC Therapeutics, Inc. (NASDAQ:PTCT), sold a total of 20,000 shares of the company's common stock on September 16 and 17, 2026. These transactions were carried out through Section Six Partners, L.P. under a pre-established Rule 10b5-1 trading plan adopted on May 14, 2026. Following these sales, Schmertzler indirectly holds 1,296,594 shares and directly holds 163,266 shares, while disclaiming beneficial ownership of shares held by Section Six Partners, L.P. except for his pecuniary interest.